Friday 17^th November 2017

13:20      Welcome and introduction (D. Betticher, Fribourg)

Open questions in lymphoma and CLL (A. Moccia)

13:30      The new WHO classification: what changes for the clinician? (S. Dirnhofer, Basel)

14:10      Has PET replaced all other imaging in lymphoma? (L. Ceriani, Bellinzona)

14:50      Does radiotherapy still have a role in lymphoma treatment? (T. Illidge, Manchester)

15:30      Coffee Break

16:00      Should all treatments of Hodgkin lymphoma be (PET-)response-adapted? (A. Moccia, Bellinzona)

16:40      Is genetics-based treatment of DLBCL ready to be applied to patients? (U. Novak, Bern)

17:20      Burkitt and lymphoblastic lymphoma: which regimens should we use? (F. Stenner, Basel)

18:00      Adjourn

Saturday 18^th November 2017

Open questions in lymphoma and CLL (M. Ghielmini)

08:00      T-cell lymphomas: any progress in the last 20 years? (F. Hitz, St. Gallen)

08:40      Is there a standard treatment for Mantle Cell lymphoma? (U. Mey, Chur)

09:20      CNS lymphoma and CNS prophylaxis: is high-dose chemo the solution? (A. Ferreri, Milano)

10:00      Coffee Break

10:30      Follicular lymphoma: the end of chemotherapy? (M. Ghielmini, Bellinzona)

11:10      Should Marginal Zone lymphomas be treated as follicular lymphomas? (M. Raderer, Vienna)

11:50      CLL: have new drugs made allogeneic transplantation obsolete? (D. Rossi, Bellinzona)

12:30      Wrap up and closure